We are live on !
Find out more
Dmitry Balyasny Balyasny Asset Management
AUM
$80.2B
Turnover
42.78%
1-Year Est. Return
51.53%
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
This Fund
S&P 500
This Quarter Est. Return
+19.41%
1 Year Est. Return
+51.53%
3 Year Est. Return
+149.76%
5 Year Est. Return
+199.38%
10 Year Est. Return
+875.18%
AUM
$80.2B
AUM Growth
+$3.12B
(+4%)
Cap. Flow
-$3.01B
Cap. Flow % of AUM
Cap. Flow %
-3.76%
Top 10 Holdings %
Top 10 Hldgs %
13.57%
Holding
3,665
New
834
Increased
989
Reduced
995
Closed
734
Avg Time Held
Equity + Options
1.1
years
Top 10 Avg Time Held
Equity + Options
0.8
years
Top 20 Avg Time Held
Equity + Options
0.8
years
Avg Time Held Equity only
0.9
years
Top 10 Avg Time Held Equity only
0.4
years
Top 20 Avg Time Held Equity only
0.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SpaceX
SPCX
|
+$577M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$538M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$517M |
| 4 |
Texas Instruments
TXN
|
+$413M |
| 5 |
Roku
ROKU
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Hologic
HOLX
|
+$357M |
| 2 |
Meta Platforms (Facebook)
META
|
+$326M |
| 3 |
Johnson Controls International
JCI
|
+$303M |
| 4 |
Applied Materials
AMAT
|
+$285M |
| 5 |
Coterra Energy
CTRA
|
+$285M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 36.95% |
| 2 | Technology | 12.69% |
| 3 | Industrials | 9.95% |
| 4 | Consumer Discretionary | 8.03% |
| 5 | Healthcare | 7.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
826
PUT
American Express
AXP
$213B
| $14.8M | 0.02% |
43,700
+4,500
| +11% | +$1.44M |
2023 Q3
11 quarters
|
|
827
Imperial Oil
IMO
$63.2B
| $14.8M | 0.02% |
131,539
+127,638
| +3,272% | +$16M |
2026 Q1
1 quarter
|
|
828
Chewy
CHWY
$8.3B
| $14.8M | 0.02% |
751,174
-600,270
| -44% | -$13.6M |
2024 Q2
8 quarters
|
|
829
PUT
Kinder Morgan
KMI
$74.8B
| $14.8M | 0.02% |
461,400
+74,300
| +19% | +$2.39M |
2026 Q1
1 quarter
|
|
830
Hertz
HTZ
$677M
| $14.7M | 0.02% |
6,505,105
+4,487,472
| +222% | +$24.5M |
2024 Q4
6 quarters
|
|
831
Viavi Solutions
VIAV
$8.47B
| $14.7M | 0.02% |
308,561
-136,518
| -31% | -$6.54M |
2024 Q3
7 quarters
|
|
832
Zegna
ZGN
$3.57B
| $14.7M | 0.02% |
1,131,031
+576,398
| +104% | +$7.43M |
2025 Q4
2 quarters
|
|
833
Pultegroup
PHM
$22.8B
| $14.7M | 0.02% |
107,295
-506,375
| -83% | -$61.5M |
2025 Q1
5 quarters
|
|
834
DELISTED
Esperion Therapeutics
ESPR
| $14.7M | 0.02% |
+4,654,778
| New | +$13M |
2026 Q2
0 quarters
|
|
835
RenaissanceRe
RNR
$13.8B
| $14.7M | 0.02% |
+46,380
| New | +$13.9M |
2026 Q2
0 quarters
|
|
836
Motorola Solutions
MSI
$80B
| $14.7M | 0.02% |
35,351
-285,069
| -89% | -$119M |
2023 Q2
12 quarters
|
|
837
ScottsMiracle-Gro
SMG
$3.47B
| $14.7M | 0.02% |
215,537
+138,931
| +181% | +$8.61M |
2025 Q3
3 quarters
|
|
838
SAB Biotherapeutics
SABS
$291M
| $14.7M | 0.02% |
3,760,439
| – | – |
2025 Q4
2 quarters
|
|
839
Prime Medicine
PRME
$972M
| $14.6M | 0.02% |
3,969,082
-154,283
| -4% | -$512K |
2025 Q3
3 quarters
|
|
840
Zenas BioPharma
ZBIO
$1.88B
| $14.6M | 0.02% |
576,717
-90,353
| -14% | -$1.8M |
2025 Q4
2 quarters
|
|
841
NextDecade
NEXT
$1.73B
| $14.5M | 0.02% |
1,926,956
-613,199
| -24% | -$4.85M |
2025 Q3
3 quarters
|
|
842
Ares Capital
ARCC
$13.4B
| $14.5M | 0.02% |
783,779
-9,930
| -1% | -$185K |
2025 Q4
2 quarters
|
|
843
PUT
Booking.com
BKNG
$111B
| $14.5M | 0.02% |
81,400
-6,100
| -7% | -$1.04M |
2023 Q3
11 quarters
|
|
844
PUT
BILL Holdings
BILL
$4.09B
| $14.5M | 0.02% |
400,000
-875,000
| -69% | -$32.2M |
2025 Q3
3 quarters
|
|
845
Cousins Properties
CUZ
$4.69B
| $14.4M | 0.02% |
481,192
+358,437
| +292% | +$9.4M |
2023 Q2
12 quarters
|
|
846
Sylvamo
SLVM
$1.27B
| $14.4M | 0.02% |
380,881
+359,687
| +1,697% | +$14.6M |
2024 Q4
6 quarters
|
|
847
First Tracks Biotherapeutics
TRAX
$1.92B
| $14.4M | 0.02% |
+714,948
| New | +$13.4M |
2026 Q2
0 quarters
|
|
848
Revolve Group
RVLV
$1.61B
| $14.4M | 0.02% |
627,133
-571,915
| -48% | -$12.7M |
2024 Q3
7 quarters
|
|
849
Helmerich & Payne
HP
$4.18B
| $14.4M | 0.02% |
+438,367
| New | +$16.4M |
2026 Q2
0 quarters
|
|
850
CALL
United Parcel Service
UPS
$89.9B
| $14.3M | 0.02% |
133,200
+120,300
| +933% | +$12.5M |
2025 Q4
2 quarters
|
|
Similar funds
Dmitry Balyasny's Q2 2026 Portfolio in Review
As of Q2 2026, Dmitry Balyasny held 3,665 positions worth $80.2B, up 4% from $77.1B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Dmitry Balyasny withdrew a net $3.01B in Q2 2026, closing 734 positions and reducing 995 holdings. Its most notable exit was Hologic, an estimated $357M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 37% of assets, down from 39% a quarter earlier, followed by Technology and Industrials.
Against the trend, Dmitry Balyasny opened a new position in SpaceX worth $581M.
- Dmitry Balyasny's largest Q2 2026 buy was SpaceX: 3,397,642 shares worth $581M.
- Dmitry Balyasny added most to State Street SPDR S&P 500 ETF Trust in Q2 2026, an estimated $538M increase.
- Dmitry Balyasny's biggest Q2 2026 reduction was Meta Platforms (Facebook), cutting an estimated $326M.
- Dmitry Balyasny fully exited Hologic in Q2 2026, selling an estimated $357M.
- Dmitry Balyasny's ten largest holdings make up 14% of its $80.2B portfolio in Q2 2026.
- Dmitry Balyasny opened 834 new positions and closed 734 in Q2 2026.
- Dmitry Balyasny's portfolio value rose 4% quarter-over-quarter to $80.2B.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.